| 상품명칭 |
부프레노르핀 B-D-글루쿠로나이드 |
| 별명 |
(57-17-(시클로프로필메틸)-4,5-에폭시-18,19-디하이드로-7-[(1S)-1-히드록시-1,2,2,-트리메틸프로필]-6-메톡시-6,14-에테노모르피난-3-일-b-D-글루쿠로나이드; 부프레노르핀-3-O-글루쿠로나이드; (5,7)-17-(시클로프로필메틸)-4,5-에폭시-18,19-디하이드로-7-[(1S)-1-히드록시-1,2,2,-트리메틸프로필]-6-메톡시-6,14-에테노모르피난-3-일-D-글루쿠로나이드; 부프레노르핀 -D-글루쿠로나이드; (5alpha, 6beta, 14beta, 18R) -17- (cyclopropylmethyl) -18- [(2S) -2- 히드 록시 -3,3- 디메틸 부탄 -2- 일] -6- 메 톡시 -18,19- 디 하이드로 -4,5- 에폭시 -6,14- 에테 노 모르 피난 -2- 일 베타 -D- 글루 코피 라노 시 듀 론산 |
| 영문 이름 |
BUPRENORPHINE B-D-GLUCURONIDE;(57-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2,-trimethylpropyl]-6-methoxy-6,14-ethenomorphinan-3-yl b-D-Glucuronide; buprenorphine-3-O-glucuronide; (5,7)-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2,-trimethylpropyl]-6-methoxy-6,14-ethenomorphinan-3-yl -D-Glucuronide; Buprenorphine -D-Glucuronide; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-2-yl beta-D-glucopyranosiduronic acid |
| 분자식 |
C35H49NO10 |
| 분자량 |
643.7643 |
| InChI |
InChI=1/C35H49NO10/c1-31(2,3)32(4,42)21-15-33-8-9-35(21,43-5)30-34(33)10-11-36(16-17-6-7-17)22(33)13-18-12-19(14-20(45-30)23(18)34)44-29-26(39)24(37)25(38)27(46-29)28(40)41/h12,14,17,21-22,24-27,29-30,37-39,42H,6-11,13,15-16H2,1-5H3,(H,40,41)/t21-,22-,24+,25+,26-,27+,29-,30-,32+,33-,34+,35-/m1/s1 |
| cas번호 |
101224-22-0 |
| 분자 구조 |
|
| 밀도 |
1.43g/cm3 |
| 굴절 지수 |
1.657 |
| 위험성 표시 |
|
| 리스크 규칙 |
|
| 보안 규칙 |
|
|
